We are live on ! Find out more
AAA

Affinity Asset Advisors Portfolio holdings

AUM $1.94B
1-Year Est. Return 374.45%
This Fund
S&P 500
This Quarter Est. Return
+72.19%
1 Year Est. Return
+374.45%
3 Year Est. Return
+1,279.72%
5 Year Est. Return
+2,528.28%
10 Year Est. Return
–
AUM
$1.15B
AUM Growth
+$416M
Cap. Flow
+$154M
Cap. Flow %
13.42%
Top 10 Hldgs %
42.31%
Holding
115
New
23
Increased
29
Reduced
19
Closed
19

Top Buys

Rank Stock Value
1
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$54.2M
2
APGE icon
Apogee Therapeutics
APGE
+$18.4M
3
ABVX
Abivax
ABVX
+$15.9M
4
SLNO
Soleno Therapeutics
SLNO
+$14.8M
5
CYTK icon
Cytokinetics
CYTK
+$14.4M

Top Sells

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$32M
2
PTGX icon
Protagonist Therapeutics
PTGX
+$12.5M
3
TVTX icon
Travere Therapeutics
TVTX
+$8.84M
4
INZY
Inozyme Pharma
INZY
+$7M
5
VERA icon
Vera Therapeutics
VERA
+$5.59M

Sector Composition

Rank Sector Weight
1 Healthcare 85.26%
2 Financials 0.33%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RVMD icon
51
Revolution Medicines
RVMD
$39.9B
$4.67M 0.41%
+100,000
New +$3.92M
OMER icon
52
PUT
Omeros
OMER
$716M
$4.65M 0.41%
1,133,900
+819,900
+261% +$3.25M
PCVX icon
53
Vaxcyte
PCVX
$7.89B
$4.5M 0.39%
125,000
– –
NAMSW icon
54
NewAmsterdam Pharma Warrant
NAMSW
$4.19M 0.37%
245,000
– –
PCSC
55
DELISTED
Perceptive Capital Solutions
PCSC
$3.76M 0.33%
350,000
– –
INSP icon
56
Inspire Medical Systems
INSP
$1.44B
$3.71M 0.32%
+50,000
New +$5.06M
OVID icon
57
Ovid Therapeutics
OVID
$435M
$3.44M 0.3%
2,650,000
+1,982,484
+297% +$1.72M
BBIO icon
58
BridgeBio Pharma
BBIO
$16.4B
$3.38M 0.29%
65,000
-85,000
-57% -$4.15M
JAZZ icon
59
Jazz Pharmaceuticals
JAZZ
$15.9B
$3.29M 0.29%
25,000
– –
CRNX icon
60
Crinetics Pharmaceuticals
CRNX
$8.86B
$3.12M 0.27%
75,000
-77,252
-51% -$2.47M
MBX
61
MBX Biosciences
MBX
$2.95B
$2.89M 0.25%
+165,000
New +$2.21M
AUTL
62
Autolus Therapeutics
AUTL
$391M
$2.85M 0.25%
1,750,000
-1,295,000
-43% -$2.53M
OCUL icon
63
Ocular Therapeutix
OCUL
$1.86B
$2.79M 0.24%
+239,000
New +$2.86M
OACCU
64
Oaktree Acquisition Corp III Life Sciences Unit
OACCU
$2.66M 0.23%
250,000
– –
CLYM
65
Climb Bio
CLYM
$728M
$2.61M 0.23%
1,300,000
-200,000
-13% -$371K
OLMA icon
66
CALL
Olema Pharmaceuticals
OLMA
$1.02B
$2.45M 0.21%
+250,000
New +$1.5M
OLMA icon
67
Olema Pharmaceuticals
OLMA
$1.02B
$2.45M 0.21%
250,000
– –
SGMT icon
68
Sagimet Biosciences
SGMT
$438M
$2.4M 0.21%
+350,000
New +$2.84M
ATXS
69
DELISTED
Astria Therapeutics
ATXS
$2.18M 0.19%
300,000
– –
UTHR icon
70
United Therapeutics
UTHR
$26.4B
$2.1M 0.18%
+5,000
New +$1.68M
GERN icon
71
Geron
GERN
$924M
$2.06M 0.18%
1,500,000
– –
AVR
72
Anteris Technologies
AVR
$787M
$2.02M 0.18%
450,000
+25,000
+6% +$98K
OBIO icon
73
Orchestra BioMed
OBIO
$227M
$1.8M 0.16%
+727,272
New +$2.01M
EPRX
74
Eupraxia Pharmaceuticals
EPRX
$383M
$1.77M 0.15%
+300,000
New +$1.63M
CGEM icon
75
Cullinan Oncology
CGEM
$1.07B
$1.56M 0.14%
263,817
– –
1 2
3
4 5

Similar funds

FM
Foster & Motley Cincinnati, Ohio $1.94B AUM 21.65% 1-Year Est. Return
1SB
1ST Source Bank South Bend, Indiana $1.94B AUM 20.3% 1-Year Est. Return
HCL
Heard Capital LLC Chicago, Illinois $1.93B AUM 21.66% 1-Year Est. Return
OCM
Osterweis Capital Management San Francisco, California $1.94B AUM 20.77% 1-Year Est. Return
HC
Hamilton Capital Columbus, Ohio $1.93B AUM
FFH
Fairfax Financial Holdings Toronto, Ontario, Canada $1.94B AUM 27.76% 1-Year Est. Return
BC
Blackhill Capital Morristown, New Jersey $1.94B AUM 18.09% 1-Year Est. Return
WPC
Waters Parkerson & Co New Orleans, Louisiana $1.95B AUM 15.9% 1-Year Est. Return

Affinity Asset Advisors's Q3 2025 Portfolio in Review

As of Q3 2025, Affinity Asset Advisors held 115 positions worth $1.15B, up 57% from $732M the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Affinity Asset Advisors deployed $154M of net new capital in Q3 2025, opening 23 new positions and adding to 29 existing holdings. Its largest new stake was State Street SPDR S&P 500 ETF Trust: 84,490 shares worth $56.3M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 88% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Protagonist Therapeutics, an estimated $12.5M trimmed.

  • Affinity Asset Advisors's largest Q3 2025 buy was State Street SPDR S&P 500 ETF Trust: 84,490 shares worth $56.3M.
  • Affinity Asset Advisors added most to Apogee Therapeutics in Q3 2025, an estimated $18.4M increase.
  • Affinity Asset Advisors's biggest Q3 2025 reduction was Protagonist Therapeutics, cutting an estimated $12.5M.
  • Affinity Asset Advisors fully exited Blueprint Medicines in Q3 2025, selling an estimated $32M.
  • Affinity Asset Advisors's ten largest holdings make up 42% of its $1.15B portfolio in Q3 2025.
  • Affinity Asset Advisors opened 23 new positions and closed 19 in Q3 2025.
  • Affinity Asset Advisors's portfolio value rose 57% quarter-over-quarter to $1.15B.

Based on Affinity Asset Advisors's 13F filing for Q3 2025, filed 13 Nov 2025.